HIGHLIGHTS
- who: Cang Li and collaborators from the Skin Disease Research Institute, Zhejiang University School of Medicine, Hangzhou, China have published the research: Melanogenesis and the Targeted Therapy of Melanoma, in the Journal: Biomolecules 2022, 1874 of /2022/
SUMMARY
MART-1 siRNA inhibits PMEL17 processing in_vitro to repress the PMEL17 expression. KRAS or HRAS mutations are detected infrequently in approximately 5% of melanoma patients, whereas NRAS mutations (NRASmut) are found in about 25% of patients, which makes NRAS the second most frequent mutation type after BRAF in melanoma. STK19 inhibitors inhibitors was effective in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.